Novel localization of peripherin 2, the photoreceptor-specific retinal degeneration slow protein, in retinal pigment epithelium by Uhl, Patrizia B. et al.
Int. J. Mol. Sci. 2015, 16, 2678-2692; doi:10.3390/ijms16022678 
 





Novel Localization of Peripherin 2, the Photoreceptor-Specific 
Retinal Degeneration Slow Protein, in Retinal  
Pigment Epithelium 
Patrizia B. Uhl 1, Barbara Amann 1, Stefanie M. Hauck 2 and Cornelia A. Deeg 1,* 
1 Institute for Animal Physiology, Department of Veterinary Sciences,  
Ludwig-Maximilians-University, Veterinärstraße 13, D-80539 Munich, Germany;  
E-Mails: p.uhl@tiph.vetmed.uni-muenchen.de (P.B.U.);  
baerbl.amann@tiph.vetmed.uni-muenchen.de (B.A.) 
2 Research Unit for Protein Science, Helmholtz Zentrum München, German Research Center for 
Environmental Health GmbH, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany;  
E-Mail: hauck@helmholtz-muenchen.de 
* Author to whom correspondence should be addressed;  
E-Mail: deeg@tiph.vetmed.uni-muenchen.de; Tel.: +49-89-2180-1630; Fax: +49-89-2180-2554. 
Academic Editor: Johannes Haybaeck 
Received: 5 December 2014 / Accepted: 22 January 2015 / Published: 26 January 2015 
 
Abstract: Retinal pigment epithelium (RPE) builds the outer blood-retinal barrier of the 
eye. Since one typical feature of the autoimmune disease, equine recurrent uveitis (ERU), 
is the breakdown of this barrier, we recently performed comparative analysis of healthy 
and uveitic RPE. We identified for the first time peripherin 2, which is responsible for 
visual perception and retina development, to be localized in RPE. The purpose of this  
study was therefore to validate our findings by characterizing the expression patterns of 
peripherin 2 in RPE and retina. We also investigated whether peripherin 2 expression 
changes in ERU and if it is expressed by the RPE itself. Via immunohistochemistry, 
significant downregulation of peripherin 2 in uveitic RPE compared to the control was 
detectable, but there was no difference in healthy and uveitic retina. A further interesting 
finding was the clear distinction between peripherin 2 and the phagocytosis marker, 
rhodopsin, in healthy RPE. In conclusion, changes in the expression pattern of peripherin 2 
selectively affect RPE, but not retina, in ERU. Moreover, peripherin 2 is clearly detectable 
in healthy RPE due to both phagocytosis and the expression by the RPE cells themselves. 
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Our novel findings are very promising for better understanding the molecular mechanisms 
taking place on RPE in uveitis. 
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1. Introduction 
Autoimmune uveitis is a sight-threatening disease mediated by autoreactive T-cells that cross  
the blood-retinal barrier with subsequent inflammation of the inner eye and destruction of retinal 
structures [1]. Until now, molecular mechanisms of pathophysiology leading to the loss of the  
immune-privilege of the inner eye are not fully understood. The only spontaneous animal model for 
autoimmune uveitis in man is equine recurrent uveitis (ERU), a remitting-relapsing disease of horses 
that results in blindness [2,3]. There are many similarities in clinical presentation, the course of the 
disease and autoimmune reactions between human autoimmune uveitis patients and ERU cases [2,4]. 
These resemblances and the fact that intraocular tissue samples are available from horses in all stages 
of disease, which have an outbred genetic background and are exposed to all typical environmental 
conditions, render ERU an ideal model for uveitis in man. Thus, investigating pathomechanisms 
contributing to this frequently occurring eye disease of horses has become very important [2,5]. 
Retinal pigment epithelium (RPE) builds the outer blood-retinal barrier [6] and is the crucial part  
of the immune defense of the eye [7]. We started with in-depth molecular analysis of RPE cells by 
creating an equine cell line and comparing the cell surface proteome of Passage 4 equine RPE cells 
and native cells [6]. Since there was a significant alteration between cell surface proteomes of native 
and cultured cells, the suitability of cultured cells for molecular analyses was affected [6]. Thus, in a 
follow-up study, we used in situ labelling of tissue samples in very short post-mortem times, which 
enabled the identification of 148 RPE cell surface proteins, potentially representing their appearance in 
physiological and pathophysiological in vivo processes [5]. 
Among these 148 proteins, 27 were differentially expressed between healthy and ERU cases [5]. 
Surprisingly, one of the differentially expressed proteins, detected in equine RPE, was peripherin 2, 
which is, under normal physiological conditions, responsible for visual perception and retina 
development [5]. Peripherin 2 is known to be selectively expressed in the photoreceptor outer segment 
of the retina [8], and mutations in the peripherin 2 gene are commonly associated with retinal 
degenerative diseases, like retinitis pigmentosa and autosomal dominant macular dystrophy in man [9]. 
However, until now, there was no information about peripherin 2 expression in RPE and whether 
expression changes of peripherin 2 were associated with autoimmune uveitis. 
Therefore, the goal of this study was to validate our novel finding of peripherin 2 localization  
to equine, as well as to human RPE cells and to characterize the respective expression patterns of 
peripherin 2 in physiological and uveitic equine eyes. 
  




2.1. Peripherin 2 Locates to the Photoreceptor Outer Segments of Equine Retina with no Significant 
Difference between Healthy and ERU Diseased Samples 
Mutations in the peripherin 2 gene are associated with many human retinal degenerative diseases, 
like retinitis pigmentosa and adult vitelliform macular dystrophy [8]. Therefore, and due to the fact 
that, to our knowledge, there was no information about the expression pattern of peripherin 2 in equine 
retina, we were interested in assessing its physiological expression pattern, as well as its disease-associated 
changes. We thus performed antibody-based staining of healthy and uveitic retinal sections (Figure 1). 
Differential interference contrast (DIC) images show representative retinas of healthy (Figure 1A–D) 
and diseased (Figure 1E–H) horses. In healthy equine retina, peripherin 2 was detectable in 
photoreceptor outer segments with equal intensity along the whole intact photoreceptor layer (Figure 1B, 
peripherin 2 = red). Interestingly, the same expression pattern was found in ERU diseased retinas 
(early stages), where peripherin 2 was also localized in the thinner, but still completely intact, 
photoreceptor outer segments with a similar intensity and distribution (Figure 1F, peripherin 2 = red) 
as in healthy equine retinas (Figure 1B, peripherin 2 = red). Since rhodopsin is a typical photoreceptor 
marker [10], we were interested in its expression pattern in healthy and uveitic equine retinae 
compared to the expression pattern of peripherin 2. Therefore, sections stained with anti-peripherin 2 
were also stained with anti-rhodopsin. Like peripherin 2, rhodopsin was detectable in photoreceptor 
outer segments with an equal distribution and intensity in healthy retina sections (Figure 1C,  
rhodopsin = green). The same expression pattern of rhodopsin was found in ERU diseased retinas 
(Figure 1G, rhodopsin = green). In addition, the overlay of peripherin 2 and rhodopsin showed the 
same expression pattern in healthy (Figure 1D, peripherin 2 = red, rhodopsin = green, overlap of 
peripherin 2 and rhodopsin = yellow), as well as in uveitic retinae (Figure 1H, peripherin 2 = red, 
rhodopsin = green, overlap of peripherin 2 and rhodopsin = yellow). 
 
Figure 1. Cont. 




Figure 1. Expression pattern of peripherin 2 (red) and rhodopsin (green) in representative 
retinas of healthy (left) and equine recurrent uveitis (ERU) cases (right). Differential 
interference contrast image of healthy (A) and diseased (E) equine retina. Peripherin 2 
(red) was equally distributed in the photoreceptor outer segments of healthy (B) and 
diseased (F) equine retina. Cell nuclei were stained with 4',6-diamidino-2-phenylindol 
(DAPI) (blue); Rhodopsin (green) was also equally distributed in photoreceptor outer 
segments of healthy (C) and uveitic (G) retinas. The overlap of peripherin 2 and rhodopsin 
in healthy (D) and uveitic (H) retina show overlapping expression pattern of both  
proteins (yellow). 
2.2. Peripherin 2 Is Detectable in Healthy Equine RPE Cells and Downregulated in Uveitic Cases 
Peripherin 2 was known to be localized in photoreceptor outer segments of mouse, rat and bovine 
retina [11,12]. In this study, we found a similar expression pattern in photoreceptor outer segments in 
horse retina (Figure 1). Interestingly, in a prior study, we detected peripherin 2 on the cell surface of 
RPE cells using in situ biotinylation followed by LC-MS/MS [5]. Since the peripherin 2 expression 
pattern in RPE was not described yet, we performed immunohistochemistry to localize peripherin 2  
in healthy equine RPE and to examine ERU-associated changes in diseased equine RPE (Figure 2).  
In order to exclude the correlation of decreased peripherin 2 expression with the destruction of 
diseased RPE cells in advanced stages of ERU, we only investigated morphologically intact RPE  
of ERU cases. Thus, DIC images of healthy (Figure 2A) and diseased (Figure 2E) equine RPE showed 
a morphologically intact RPE monolayer in both cases. In healthy equine RPE, peripherin 2 was 
expressed across the whole cell and along the whole RPE layer, excluding the apical rim (Figure 2B, 
peripherin 2 = red). In addition, the intensity of peripherin 2 was constant throughout the entire healthy 
RPE with some enhanced spots (Figure 2B, peripherin 2 = red). Interestingly, immunohistochemical 
staining of RPE of diseased horses revealed a significant reduction of peripherin 2 expression in 
uveitic RPE (Figure 2F, peripherin 2 = red, the same specimen as shown in Figure 1E–H). 
Accordingly, expression changes of peripherin 2 selectively concerned RPE cells, but not 
photoreceptor outer segments in ERU cases (Figures 1E–H and 2E,F, the same ERU case).  
Peripherin 2 expression was limited to a few small spots in diseased RPE, and the intensity of 
Int. J. Mol. Sci. 2015, 16 2682 
 
 
peripherin 2 was significantly reduced (Figure 2F, peripherin 2 = red) compared to healthy controls 
(Figure 2B, peripherin 2 = red). Since RPE cells are the most active phagocytic cells in the body [10], 
it seemed obvious that peripherin 2 gets into RPE by phagocytosis. In order to pursue this thought,  
we double stained RPE sections for peripherin 2 and rhodopsin (Figure 2). We decided to use 
rhodopsin, because it is known to be phagocytized within photoreceptor outer fragments by RPE, 
making rhodopsin a suitable marker for phagocytic processes [13,14]. Both in healthy (Figure 2C,  
rhodopsin = green) and in uveitic (Figure 2G, rhodopsin = green) RPE, rhodopsin was typically 
concentrated in a few spots, which were distributed over the whole RPE layer. In contrast to  
peripherin 2 (Figure 2B,F, peripherin = red), the rhodopsin localization pattern was unchanged in 
uveitic RPE compared to healthy controls. Regarding the overlap of the two proteins, it becomes 
apparent that the spots expressing rhodopsin were also clearly positive for peripherin 2 (Figure 2D,H, 
overlap of peripherin 2 and rhodopsin = yellow). Besides, peripherin 2 was constantly expressed 
throughout the entire remaining parts of healthy RPE (Figure 2D, peripherin 1 = red, rhodopsin = green, 
overlap of peripherin 2 and rhodopsin = yellow). In contrast, in uveitic RPE, downregulation of 
peripherin 2 was clearly detectable, and only spots stained positive for rhodopsin were also positive for 
peripherin 2 (Figure 2H, overlap of peripherin 2 and rhodopsin = yellow). 
 
Figure 2. Peripherin 2 (red) and rhodopsin (green) expression in retinal pigment 
epithelium (RPE) of representative healthy (left) and ERU cases (right). Differential 
interference contrast image of healthy (A) and diseased (E) equine RPE. In healthy (B) 
RPE, peripherin 2 was expressed over the entire RPE cell layer, and the intensity was 
enhanced in some spots. In uveitic RPE cells (F), peripherin 2 was significantly reduced to 
few small spots; Rhodopsin was limited to few isolated spots, distributed throughout the 
whole RPE layer, in healthy (C), as well as in diseased (G) RPE. The overlap of peripherin 2 
and rhodopsin in healthy (D) RPE indicates significant higher expression of peripherin 2 
compared to rhodopsin (the yellow overlap is only displayed in a few spots). In uveitic 
RPE (H), peripherin 2 was only expressed at rhodopsin expression sites (yellow spots). 
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2.3. Expression Changes of Peripherin 2 Selectively Concerned RPE Cells, but not Photoreceptor 
Outer Segments in ERU Cases 
To quantify the expression of peripherin 2 and rhodopsin, fluorescence intensities of healthy and 
uveitic retinas and RPE were measured and analyzed (Figure 3). A comparison of the fluorescence 
intensity of peripherin 2 in healthy retinas (Figure 3A, grey column, 100% ± 22.8%) and uveitic 
retinas (Figure 3A, black column, 110.4% ± 32.9%) revealed no significant difference of protein 
expression in photoreceptors. A similar result was shown for the quantification of the fluorescence 
intensity of rhodopsin in healthy (Figure 3B, grey column, 100% ± 8.6%) and uveitic (Figure 3B, 
black column, 104.1% ± 5.8%) photoreceptor outer segments. In addition, rhodopsin expression  
in healthy RPE (Figure 3D, grey column, 100% ± 7.8%) did not significantly differ from uveitic  
RPE (Figure 3D, black column, 103.9% ± 5.1%). In contrast, the mean fluorescence intensity of 
peripherin 2 in equine RPE cells of ERU cases (Figure 3C, black column) was significantly reduced to 
17.9% ± 5% (** p ≤ 0.01) of the physiological expression in healthy controls (Figure 3C, grey column, 
100% ± 28.1%). 
 
Figure 3. (A) Quantification of the fluorescence intensity of peripherin 2 expression in 
photoreceptor outer segments revealed no significant difference between healthy (grey 
column) and ERU cases (black column); (B) There was also no significant difference 
between the fluorescence intensity of rhodopsin in photoreceptor outer segments of healthy 
(grey column) and uveitic (black column) retinas detectable; (C) A significant reduction  
of the fluorescence intensity of peripherin 2 in uveitic RPE to 17.9% (black column), 
compared to RPE of negative controls (** p ≤ 0.01); (D) Quantification of the fluorescence 
intensity of rhodopsin in RPE showed no significant difference between healthy (grey column) 
and ERU cases (black column). 
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2.4. Cultivated RPE Cells still Express Peripherin 2 
To investigate whether RPE cells express peripherin 2 by themselves or if the protein got into RPE 
cells just by phagocytosis, we investigated the peripherin 2 expression pattern of cultivated, primary 
healthy RPE cells (Figure 4). Differential interference contrast image shows healthy RPE cells  
(Figure 4A–C) at different confluency states, from single cells (Figure 4A) up to confluent cells 
(Figure 4C). In each growth stage, peripherin 2 expression was clearly detectable over the whole RPE 
cell with an equal intensity (Figure 4D–F, peripherin 2 = red). Furthermore, we stained these healthy 
RPE cells also for rhodopsin to examine the appearance of rhodopsin compared to peripherin 2 in 
cultivated RPE cells. In contrast to peripherin 2, rhodopsin was not detectable in passaged RPE cells 
(Figure 4G–I). 
 
Figure 4. Investigation of peripherin 2 (red) and rhodopsin (green) expression on 
cultivated healthy RPE cells at different confluency states. Differential interference 
contrast image of healthy equine RPE cells at different confluency states; from single cells 
(A) to 40% confluent cells (B) up to 90%–100% confluent cells (C); (D–F) Peripherin 2 
(red) was expressed over whole RPE cells with an even intensity (cell nuclei = blue);  
(G–I) No rhodopsin (green) expression was found in primary healthy equine RPE cells 
(cell nuclei = blue). 
2.5. Peripherin 2 Is also Expressed by Human RPE 
To strengthen our novel finding of peripherin 2 existence in RPE, we wanted to investigate whether 
the expression of peripherin 2 was also detectable in human RPE cells. Therefore, we detected 
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peripherin 2 expression with immunohistochemistry in human RPE sections. Peripherin 2 staining of 
human RPE sections corresponded very well with our latest findings of the peripherin 2 distribution in 
equine RPE. As in healthy equine RPE, peripherin 2 was clearly detectable over the whole RPE layer 
with an equal intensity in human RPE (Figure 5, peripherin 2 = red). 
 
Figure 5. Peripherin 2 (red) expression in healthy human RPE. (A) Differential interference 
contrast image of healthy human RPE; (B) peripherin 2 (red) was expressed over the whole 
RPE layer with an even intensity.  
3. Discussion 
Pathogenesis and etiology of ERU, the only spontaneous animal model for human autoimmune 
uveitis, are not entirely clarified to date [3,15]. However, differential proteome analyses provided more 
insights into the molecular pathomechanisms of this spontaneously occurring disease by detecting 
several differentially-expressed proteins in uveitic vitreous, retina, sera and infiltrating leukocytes, 
which might be crucially involved in disease development and progression [2,16–20]. Since one 
characteristic feature of ERU is the breakdown of the outer blood-retinal barrier [21], the RPE is 
significantly involved in the pathophysiological processes of uveitis. Thus, we recently performed 
comparative analysis of the plasma cell membrane proteomes of healthy and uveitic RPE cells in situ 
to gain a better understanding of the pathomechanisms leading to the breakdown of the blood-retinal 
barrier [5]. Interestingly, one of the differentially-expressed plasma cell membrane proteins was 
peripherin 2, which is, under normal physiological conditions, responsible for visual perception and 
retina development (according to GO terminology). Peripherin 2 was found to be substantially 
downregulated in ERU cases [5]. In the present study, we were now able to validate this novel 
localization of peripherin 2 in physiological equine RPE (Figure 2) and its significant downregulation 
in ERU (Figures 2 and 3). Moreover, we were able to detect peripherin 2 in human RPE (Figure 5). 
Then, we further characterized the expression pattern of peripherin 2 in equine RPE, and thereby,  
we could show the localization of peripherin 2 in the whole healthy RPE cell, whereas in our  
previous study, we only knew about the occurrence in the plasma cell membrane [5]. Furthermore,  
we demonstrated that peripherin 2 is localized with an even intensity in the photoreceptor outer 
segments of rods and cones in physiological equine retina (Figure 1). So far, a similar expression 
pattern of peripherin 2 within photoreceptor outer segments was detected in other species, like cows, 
rats and mice [12,22]. 
Even more interesting, in our point of view, is the novel finding of peripherin 2 expression in 
equine (Figure 2) and human (Figure 5) RPE cells. To our knowledge, the localization of peripherin 2 
in RPE was not described in other species so far. One question was how peripherin 2 gets in this 
position. Since one of the main functions of RPE cells is phagocytosis of photoreceptor outer 
fragments (10% per day) [13], it seemed obvious that peripherin 2 is phagocytized and, hence, to be 
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found in the phagosomes of RPE cells. As rhodopsin is a major protein in photoreceptor outer 
segments, it is already known to be phagocytized by RPE cells and, therefore, used as a marker  
for phagocytosis activity [14]. Thus, we investigated possible co-localization of rhodopsin and  
peripherin 2 in equine RPE, which would indicate an association of peripherin 2 with RPE 
phagocytosis. Double-stainings of rhodopsin and peripherin 2 in healthy RPE revealed peripherin 2 
distribution over the whole RPE layer, whereas rhodopsin was concentrated to a few spots (Figure 2). 
This localization pattern of peripherin 2 and rhodopsin led to the following assumption: spots staining 
positive for rhodopsin are presumably phagosomes, containing photoreceptor outer segment waste, 
including rhodopsin. As peripherin 2 was also localized in these spots, it can be concluded that 
peripherin 2, like rhodopsin, is phagocytized by RPE cells. Recently, the co-localization and 
interaction of peripherin 2 and rhodopsin in photoreceptor outer segments were detected for the first 
time by in vitro (HEK293 cells) and in vivo (mouse retina) co-immunoprecipitation and fluorescence 
resonance energy transfer [23]. It was shown that peripherin 2 was required as a molecular linker 
between rhodopsin and the rod cyclic nucleotide-gated channel [23]. Thereby, peripherin 2 binds to 
rhodopsin with high affinity, comparable to that of rhodopsin dimers [23]. These findings further 
strengthen our thesis that peripherin 2 is phagocytized in the same manner as rhodopsin by RPE cells. 
However, we found peripherin 2 not only in co-localization with rhodopsin, but also equally 
distributed over the whole healthy RPE (Figure 2). Therefore, it seems obvious that peripherin 2 is 
additionally expressed by RPE cells. To prove this presumption, we stained healthy cultivated RPE 
cells with anti-peripherin 2 and anti-rhodopsin antibodies. In contrast to rhodopsin, which was not 
found in cultivated RPE cells, peripherin 2 was detectable over the whole cell (Figure 4).  
In conclusion, peripherin 2 gets into RPE cells by phagocytosis, but is additionally expressed by 
healthy RPE cells themselves. 
In uveitic RPE sections, no difference between rhodopsin and peripherin 2 localization was 
detectable, and overlapping of both stainings was found in a few spots, mainly localized in the basal 
side of RPE layer (Figure 2). Thus, localization of phagosomes in healthy compared to uveitic RPE 
leads to another interesting finding: there was no detectable alteration in the RPE engulfment 
capability of ERU diseased horses in the stages of disease, in which RPE cells are morphologically 
still intact. However, whether the degradation of photoreceptor outer segments is affected in the case 
of uveitis or not has to be clarified in further studies by in vitro phagocytosis assays, for example.  
A model for an eye disease in which altered phagocytosis activity of diseased RPE cells was associated 
with pathomechanisms leading to progressive and irreversible central vision loss is Best’s disease,  
an inherited degenerative disease of human macula, which is caused by mutations in the RPE gene, 
bestrophin 1 [24]. By performing phagocytosis assays with rhodopsin, a delayed degradation of 
photoreceptor outer segments occurred in RPE cells of Best disease compared to controls, which led to 
reduced clearance of photoreceptor outer segments [24]. 
Also of high interest are the known functional features of peripherin 2 in photoreceptors, like the 
responsibility for tissue morphogenesis and stability, as well as membrane fusion processes [23], since 
they are also very important functions of RPE. Therefore, downregulated peripherin 2 in uveitic RPE 
(Figures 2 and 3) could lead to functional restrictions of RPE in ERU cases. To what extent peripherin 2  
is associated with the breakdown of the blood-retinal barrier in uveitic cases is still being investigated. 
Interestingly, even though peripherin 2 was never described with changed expression in uveitis before, 
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it is very often involved in retinal pathologies, such as adult-onset foveomacular vitelliform dystrophy, 
pattern dystrophies, cone-rod dystrophies, retinitis pigmentosa and retinitis punctata albescens through 
mutations of the peripherin 2 gene [11,25]. The normal product of the peripherin 2 gene, the protein 
peripherin 2, was for the first time identified in 1992 by cDNA sequence analysis [26]. Up to now, 
more than 150 mutations in the peripherin 2 gene, leading to these retinal diseases, have been 
identified (available online: http://www.retina-international.org/files/sci-news/rdsmut.html). Depending 
on the particular mutation, varying retinal degenerations develop. Most closely to our findings that 
peripherin 2 expression is downregulated in uveitis (Figures 2 and 3), the nmf193 mutant mouse 
model, exhibiting a single base change in the peripherin 2 gene, showed the downregulation of 
peripherin 2 in photoreceptor outer segments [27]. In this model, downregulation of peripherin 2 
expression may directly contribute to the pathology of photoreceptor degeneration [27]. These nmf193 
mutant mice show photoreceptor outer segment defects and progressive retinal degeneration [27]. 
Since the same reduction of peripherin 2 and similar photoreceptor degeneration of the nmf193 mutant 
was also found in another, non-peripherin 2 gene-associated mouse mutant of the photoreceptor-specific 
nuclear receptor gene, Nr2e3, a direct connection between decreased peripherin 2 expression and 
photoreceptor degeneration was concluded [27]. This direct association between decreased [27]  
or absent peripherin 2 expression [28] and the degeneration of photoreceptor cells suggests that also 
the reduction of peripherin 2 in diseased RPE cells could lead to the damage of RPE cells followed by 
disruptions of cell-cell junctions with consequently increased permeability of the outer blood-retinal 
barrier. To what extent peripherin 2 reduction in uveitic RPE is essentially associated with the 
mechanisms leading to blood-retinal barrier breakdown in the case of ERU is yet to be clarified. 
Therefore, one next step could be to perform leukocyte transmigration assays through a RPE 
monolayer knocked down for peripherin 2 using siRNA. 
4. Experimental Section  
4.1. Retina and RPE Specimen 
For this study, the eyes of 19 horses (11 healthy controls and 8 spontaneous ERU cases) and of one 
human donor without a known history of eye disease were used. In detail, the eyes of 15 horses  
(7 healthy controls and 8 spontaneous ERU cases) and of one human donor were used for 
immunohistochemical stainings of retina and RPE sections, and 4 healthy equine eyes were used for 
immunocytochemical stainings. The specimens of healthy equine eyes and ERU cases were obtained 
from horses that had to be euthanized due to causes unrelated to this study. The collection and use of 
equine eyes from animals that were killed due to a research-unrelated cause were approved for the 
purposes of scientific research by the appropriate board of the veterinary inspection office, Munich, 
Germany (Permit Number 8.175.10024.1319.3). Horses were treated according to the ethical principles 
and guidelines for scientific experiments on animals according to the Assosiation for Research in 
Vision and Ophthalmology (ARVO) statement for the use of animals in ophthalmic and vision 
research. No experimental animals were used in this study. Sampling of the human donor eyes was 
approved by the local ethics committee in compliance with the tenets of the declaration of Helsinki. 
The donor gave informed consent. 
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4.2. Preparation for Immunohistochemistry 
Posterior eyecups of horses were immersion-fixed with Bouin’s solution (Sigma Aldrich, 
Deisenhofen, Germany). The human eye was obtained already fixed in formalin. The fixation was 
followed by dehydration in ascending alcohol series and slicing into pre-assigned fragments, as 
described before [29]. Afterwards, tissue blocks were embedded in paraffin, sectioned with a thickness 
of 8 µm and collected on coated slides (Superfrost Plus, Thermo Fisher Scientific, Bonn, Germany). 
4.3. Immunohistochemistry of Target Tissue 
Deparaffination of tissue sections was performed with xylol. Then, sections were rehydrated in 
descending alcohol series. Heat antigen retrieval was performed in citrate buffer at 99 °C for 15 min. 
To prevent unspecific antibody binding, sections were blocked with 1% bovine serum albumin  
in Tris-buffered saline-tween (TBS-T; 10 mM Tris, 150 mM NaCl, pH 7.2, 0.1% Tween 20) 
containing 5% normal goat serum for 40 min at room temperature. The next step was to incubate retina 
and RPE sections with primary antibody against peripherin 2 (mouse monoclonal antibody 5H2, 
directed against the 35-amino acid C-terminal segment of bovine peripherin 2, kindly provided  
by Robert S. Molday, Department of Biochemistry and Molecular Biology, University of British 
Columbia, Vancouver, BC, Canada; dilution 1:50) [26] and equine retina and RPE sections 
additionally with primary antibody against rhodopsin (rat monoclonal antibody supernatant 5G6, 
already characterized as cross-reactive with horse rhodopsin [30]) at 4 °C overnight, followed by  
a washing step with TBS-T. Then, sections were incubated with anti-mouse IgG Alexa Fluor 647 and 
anti-rat IgG Alexa Fluor 546 (both Invitrogen, Karlsruhe, Germany; dilution: 1:500), respectively, for 
30 min at room temperature. Cell nuclei were counter-stained with 4',6-diamidino-2-phenylindole 
(DAPI; Invitrogen; dilution: 1:1000). Finally, sections were mounted with glass cover slips using Roti 
Mount Fluor Care (Carl Roth, Karlsruhe, Germany). Fluorescent images were recorded using Axio 
Imager M1 and Axio Vision 4.8 software (both Zeiss, Göttingen, Germany). 
4.4. Separation of Equine RPE Cells for Immunocytochemistry 
Eyes were prepared immediately after collection as described before [5]. Briefly, the first step was 
to remove the residual periocular tissue. Eye globes were cut open circumferentially, and anterior parts 
of the eye, vitreous and neurosensory retina were carefully removed. The RPE cell layer was then 
enzymatically detached from the underlying Bruch’s membrane and choroid by filling the eyecups 
with pre-warmed dissociation buffer (40 U/mL papain, Carl Roth; 1 mM PBS/EDTA pH 7.4; 260 mM 
L-cysteine, Sigma Aldrich; 1% bovine serum albumin) and incubated at 37 °C and 5% CO2 atmosphere 
for 25 min. Afterwards, RPE cells were resuspended in dissociation buffer inside the eyecup and 
transferred into DMEM (PAN-Biotech, Aidenbach, Germany) supplemented with 10% heat-inactivated 
fetal bovine serum (FCS) and 1% penicillin/streptomycin (P/S) (both PAN-Biotech) to block the 
enzymatic activity of papain. The next step was to centrifuge the suspension at 130× g for 5 min and 
wash the RPE cells two times. Finally, RPE cells were resuspended in DMEM containing 10% FCS 
and 1% P/S, seeded into T25 cell culture flasks (Sarstedt, Nümbrecht, Germany) and cultivated at 37 °C 
and 5% CO2 atmosphere until the cells were 90%–100% confluent. Subsequently, for cell passaging, 
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medium was removed and cells were washed with PBS. To detach cells from the bottom of the flask, 
cells were incubated with Trypsin (0.05%)/EDTA (0.02%) (PAN-Biotech) at 37 °C for 5 min. Cells 
were then resuspended and collected in PBS and centrifuged at 130× g for 5 min to stop the reaction. 
Then, an appropriate number of cells was resuspended in medium, divided and transferred into a T75 
cell culture flask.  
4.5. Preparation for Immunocytochemistry 
Equine RPE cells were harvested with Trypsin (0.05%)/EDTA (0.02%) for 5 min, washed twice 
with PBS and centrifuged between washing steps at 4 °C, 130× g for 5 min. Then, they were seeded 
onto glass slides and allowed to attach and grow at 37 °C and 5% CO2 atmosphere for 48 h. Slides 
were rinsed in PBS, and after drying, they were fixed in ice cold acetone for 10 min. To prevent 
unspecific antibody binding, slides were blocked with 1% BSA in TBS-T and 5% normal goat serum 
for 40 min at room temperature. Fluorescence labelling and image acquisition was performed similarly 
as for immunohistochemistry of retina and RPE sections. 
4.6. Quantification of Fluorescence Intensities 
The fluorescence intensities of photoreceptor segments of 6 healthy and 6 diseased retina sections 
and the fluorescence intensities of RPE cells of 7 healthy and 8 diseased RPE sections were quantified 
using open source ImageJ 1.47 software (avaliabel online: http://imagej.nih.gov/ij/index.html). First, 
the area and the integrated density of the region of interest (Region 1) were measured. For background 
subtraction, the mean grey value of a region without fluorescence (Region 2) was measured. The 
following formula was used to calculate the corrected total fluorescence (CTF): 
CTF = integrated density of Region 1 − (area of Region 1 × mean grey value of Region 2) (1)
The mean value from healthy CTFs was formed and set to 100%. Statistical analyses were 
performed using the Kolmogorov–Smirnov test first to determine the data distribution. Since the 
fluorescence intensities of peripherin 2 of diseased RPE samples and controls were not normally 
distributed (Kolmogorov–Smirnov: p ≤ 0.05), the Mann–Whitney test was applied for the calculation 
of abundances. The data of the statistical analysis were considered as significant with a p-value of ≤0.05  
(* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). 
5. Conclusions 
Investigations of the changes at the outer blood-retinal barrier in the case of uveitis at the molecular 
level enabled us to gain novel important insights into the sight-threatening disease, ERU. We 
demonstrated, for the first time, that peripherin 2 is obviously detectable in healthy human, as well  
as in healthy equine RPE. Peripherin 2 gets into RPE cells by phagocytosis similarly to rhodopsin,  
but is additionally expressed by healthy RPE cells themselves. Furthermore, expression changes of 
peripherin 2 selectively concern RPE cells, but not photoreceptor outer segments in uveitic cases, 
pointing to a disease-associated role of selective peripherin 2 downregulation in the outer blood  
retinal barrier. Novel localization and characterization of peripherin 2 in healthy and uveitic RPE cells 
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is very interesting and sets the foundation for further examinations of the physiological and 
pathophysiological processes taking place in the RPE. 
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